Biotechnology

Roche Pharma, a global leader in biotechnology and pharmaceuticals, has announced a monumental investment of 1.5 billion Swiss francs (approximately Rs. 14,000 crore) in India. This marks one of the largest foreign direct investments in the country’s healthcare sector. The capital will be channeled toward expanding clinical research, strengthening manufacturing capabilities, and enhancing access to advanced therapies.

Panacea Biotec and Apotex Resolve Longstanding Legal Battle, Paving Way for Future Collaborations

Anthem Biosciences, a prominent contract research and manufacturing services (CRAMS) company, has unveiled its initial public offering (IPO) price band between Rs. 530 and Rs. 570 per share. This public issue, poised to raise substantial capital, underlines the growing appetite for biotech and pharmaceutical investments in India. Market observers anticipate strong participation given Anthem’s diversified service offerings, robust global clientele, and consistent financial growth.

Anthem Biosciences, a leading contract development and manufacturing organization (CDMO) specializing in pharmaceuticals and biotechnology, is gearing up for its highly anticipated initial public offering on July 14. The IPO, expected to raise Rs. 3,395 crore, underscores the company’s ambitions to fuel its next phase of growth by enhancing manufacturing capacities and bolstering research and development.

In a decisive step toward fostering biotechnology-led innovation and entrepreneurship, the Union government has sanctioned Rs. 20.55 crore to establish a state-of-the-art biotechnology incubation center on the Indira Gandhi Agricultural University (IGAU) campus in Raipur, Chhattisgarh. Spearheaded by the Chhattisgarh Biotechnology Promotion Society, the facility is set to become a catalyst for agri-biotech and pharma-based startups.

India’s biotechnology sector has experienced remarkable growth over the past decade, expanding from USD 35.5 billion in 2014 to USD 165.7 billion in 2024. With ambitions set on reaching USD 300 billion by 2030, the sector is transitioning from research-centric to industrial and healthcare-driven impact. At a press conference marking 11 years of progress by the Department of Biotechnology (DBT), Secretary Rajesh S.